The Boca Raton, Fla.-based company said it sold approximately 330,882 shares at $6.80 per share as part of the 30-day underwriter’s option, bringing in total gross proceeds of approximately $17.3 million before expenses.
Net proceeds from the round are slated to be used for general corporate purposes, including R&D, expansion of product lines and roll-out of new products, according to a press release.
The company originally announced the closing early last week, bringing in an initial $15 million through the sale of 2.5 million shares.
Last month, Sensus Healthcare said that it won FDA 510(k) clearance for its SRT-100+ next-gen superficial radiation therapy system.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!